Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 338 of 1,261
  1. US 11028128

    Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments

    The Regents of the University of California · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  2. US 11028153

    Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  3. US 11028126

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  4. US 11028085

    Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists

    Nimbus Saturn, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  5. US 11028083

    Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

    The Board of Regents of the University of Texas System · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  6. US 11028079

    Small molecule BET bromodomain inhibitors and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  7. US 11028061

    Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  8. US 11028068

    Somatostatin modulators and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  9. US 11028048

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  10. US 11027071

    Intradermal jet injection electroporation device

    Inovio Pharmaceuticals, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  11. US 11027007

    Recombinant metapneumovirus F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  12. US 11027001

    Therapeutic cancer vaccines derived from a novel dendritic cell line

    DCPRIME B.V. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  13. US 11027000

    AADC polynucleotides for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  14. US 11026998

    Shaped mass composition comprising exenatide

    Rani Therapeutics, LLC · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  15. US 11026974

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  16. US 11026969

    High affinity T cell receptors and uses thereof

    Adaptive Biotechnologies Corporation · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  17. US 11026960

    Esters of 2-deoxy-monosaccharides with anti proliferative activity

    The Board of Regents of the University of Texas System · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  18. US 11028444

    Survival predictor for diffuse large B cell lymphoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  19. US 11026978

    Compositions and methods for treating multiple sclerosis and related disorders

    Finch Therapeutics Holdings LLC · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  20. US 11026898

    Eutectic formulations of cyclobenzaprine hydrochloride

    TONIX PHARMA LIMITED · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  21. US 11026905

    STAT3 inhibitors

    Tvardi Therapeutics, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  22. US 11028161

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  23. US 2021163596

    IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Jun 3, 2021 · Expires May 29, 2041

    granted
  24. DE 102019218589

    Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen

    BAYER AG [DE] · Granted Jun 2, 2021 · Expires May 28, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.